Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 12/20 | 0.61 |
| ▸ | TGM2 | P21980 | 1/20 | 0.60 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.60 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.56 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.56 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.56 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.55 |
| ▸ | NT5E | P21589 | 1/20 | 0.55 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14178454 | 0.94 | KRAS (0.60) | KRASTGM2FUT5P2RY2P2RY4 | |
| SCHEMBL14178465 | 0.91 | KRAS (0.64) | KRASTGM2FUT5P2RY2P2RY4 | |
| SCHEMBL29521199 | 0.90 | P2RY2 (0.67) | KRASTGM2FUT5P2RY2P2RY4 | |
| SCHEMBL14178455 | 0.90 | KRAS (0.56) | KRASTGM2FUT5P2RY2P2RY4 | |
| SCHEMBL14178449 | 0.88 | KRAS (0.61) | KRASTGM2FUT5P2RY2P2RY4 | |
| SCHEMBL14178453 | 0.88 | KRAS (0.55) | KRASTGM2FUT5P2RY2P2RY4 | |
| SCHEMBL29351374 | 0.85 | FUT5 (0.73) | KRASTGM2FUT5P2RY2P2RY4 | |
| SCHEMBL30973673 | 0.85 | FUT5 (0.73) | KRASTGM2FUT5P2RY2P2RY4 | |
| SCHEMBL30646153 | 0.85 | FUT5 (0.73) | KRASTGM2FUT5P2RY2P2RY4 | |
| SCHEMBL29581866 | 0.85 | FUT5 (0.73) | KRASTGM2FUT5P2RY2P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080108557-A1 | Modified Proteins | NOVO NORDISK HEALTHCARE A/G (CH) | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108557-A1 | Modified Proteins | PTMS, DNPEP, STT3A | KRAS 3761/4885TGM2 111/4885FUT5 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.